New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
05:55 EDTAXAS, AXAS, BWS, BWS, DXLG, DXLG, HIBB, HIBB, PGNX, PGNX, SNMX, SNMX, ZGNX, ZGNXCompanies reporting Before the Market Open on Friday, March 15
Notable companies reporting before the opening bell on Friday include Abraxas Petroleum (AXAS), Brown Shoe Co (BWS), Destination XL Group (DXLG), Hibbett Sports (HIBB), Progenics Pharmaceuticals (PGNX), Senomyx (SNMX), and Zogenix (ZGNX).
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
06:49 EDTSNMXLagoda Investment reports 7.5% passive stake in Senomyx
Subscribe for More Information
January 27, 2015
09:45 EDTBWSBrown Shoe initiated with an Outperform at Macquarie
Subscribe for More Information
January 23, 2015
08:09 EDTPGNXProgenics relaunches Azedra Phase 2 clinical study
Progenics Pharmaceuticals announced that it has dosed the first subject in the resumed pivotal Phase 2 clinical study of Azedra in patients with malignant pheochromocytoma and paraganglioma. The trial is being conducted under a Special Protocol Assessment, or SPA, with the FDA. Progenics acquired Azedra in conjunction with its 2013 acquisition of Molecular Insight Pharmaceuticals, or MIP. The study is designed to evaluate the efficacy and safety of the administration of two therapeutic doses of Azedra in patients with malignant relapsed/refractory pheochromocytoma or paraganglioma, ultra-orphan cancers with limited treatment options. The primary objective of the study is to determine the clinical benefit of Azedra based on the proportion of study participants with a reduction of all antihypertensive medication by at least 50% for at least six months. The SPA requires that 25% of 58 evaluable patients achieve the primary endpoint. In late 2010, MIP suspended enrollment in the trial to seek additional funding. The trial has now resumed to fulfill enrollment requirements under the SPA.
06:12 EDTSNMXSenomyx announces restructuring plan, plans to reduce work force by 14%
Subscribe for More Information
06:09 EDTSNMXSenomyx, PepsiCo executes collaborative research agreeement
Senomyx (SNMX) and PepsiCo (PEP) executed an amendment to the collaborative research agreement dated April 8, 2014 related to Senomyx’s Salt-Taste Program. Under the terms of the original agreement, PepsiCo agreed to provide certain research funding for our Salt Taste Program with a focus on the identification of flavors with modifying properties intended to restore the desired salty taste in products with reduced salt through December 2014. The amendment extends the research funding and the collaborative research period for an additional year through December 31, 2015.
January 20, 2015
10:06 EDTPGNXHigh option volume stocks
Subscribe for More Information
January 16, 2015
10:01 EDTAXASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:58 EDTAXASAbraxas Petroleum downgraded to Hold at Canaccord
As previously reported, Canaccord downgraded Abraxas Petroleum to Hold from Buy based on valuation in light of weaker oil prices. Canaccord lowered its price target on Abraxas Petroleum to $2.75 from $4.
06:50 EDTAXASAbraxas Petroleum downgraded to Hold from Buy at Canaccord

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use